Jean-Sebastien Casalegno
Overview
Explore the profile of Jean-Sebastien Casalegno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
970
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mnemosyme N, Frumence E, Souply L, Heaugwane D, Traversier N, Mercier A, et al.
Influenza Other Respir Viruses
. 2025 Mar;
19(3):e70075.
PMID: 40040473
No abstract available.
2.
Moisan A, Regue H, Rahou Y, Gaymard A, Oblette A, Avon L, et al.
Clin Microbiol Infect
. 2024 Dec;
PMID: 39725080
No abstract available.
3.
Chauvel C, Horvat C, Javouhey E, Gillet Y, Hassenboehler J, Abou Chakra C, et al.
Influenza Other Respir Viruses
. 2024 Dec;
18(12):e70054.
PMID: 39702765
Background: Respiratory Syncytial Virus (RSV) is a major health concern, particularly for infants. In France, Nirsevimab, a long-acting monoclonal antibody to prevent RSV-associated lower respiratory tract infections (LRTI) was available...
4.
Horvat C, Duclaux-Loras L, Ouziel A, Butin M, Couray-Targe S, Myard-Dury A, et al.
J Pediatr
. 2024 Dec;
278:114441.
PMID: 39674538
Objective: To use a pre-COVID-19 birth cohort database to describe the clinical heterogeneity of severe acute respiratory infection (SARI) cases of the past seasons as a basis to investigate further...
5.
Kramer S, Pirikahu S, Casalegno J, Domenech de Celles M
Nat Commun
. 2024 Nov;
15(1):10066.
PMID: 39567519
Pathogen-pathogen interactions represent a critical but little-understood feature of infectious disease dynamics. In particular, experimental evidence suggests that influenza virus and respiratory syncytial virus (RSV) compete with each other, such...
6.
Fourati S, Reslan A, Bourret J, Casalegno J, Rahou Y, Chollet L, et al.
Lancet Infect Dis
. 2024 Oct;
25(3):301-311.
PMID: 39419046
Background: Nirsevimab, a long-acting monoclonal antibody, has been approved for the prevention of respiratory syncytial virus (RSV) infection in infants. In France, more than 210 000 single doses were administered...
7.
Brault A, Pontais I, Enouf V, Debeuret C, Bloch E, Paireau J, et al.
Lancet Child Adolesc Health
. 2024 Aug;
8(10):721-729.
PMID: 39208833
Background: Respiratory syncytial virus (RSV) is a major cause of hospitalisations and deaths among infants worldwide. France was one of the first countries to implement a national programme (beginning on...
8.
Holmdahl I, Bents S, Baker R, Casalegno J, Trovao N, Park S, et al.
Sci Rep
. 2024 Jun;
14(1):14527.
PMID: 38914626
Nonpharmaceutical interventions (NPIs) implemented during the COVID-19 pandemic have disrupted the dynamics of respiratory syncytial virus (RSV) on a global scale; however, the cycling of RSV subtypes in the pre-...
9.
Horvat C, Chauvel C, Casalegno J, Benchaib M, Ploin D, Nunes M
Pediatr Infect Dis J
. 2024 May;
43(9):819-824.
PMID: 38713818
Background: Respiratory syncytial virus (RSV) poses a substantial threat to infants, often leading to challenges in hospital capacity. With recent pharmaceutical developments to be used during the prenatal and perinatal...
10.
Caini S, Casalegno J, Rodrigues A, Lee V, Cohen C, Huang Q, et al.
J Infect
. 2024 Apr;
88(5):106154.
PMID: 38583722
Objectives: We aimed to study whether the percentwise age distribution of RSV cases changes over time during annual epidemics. Methods: We used surveillance data (2008-2019) from the Netherlands, Lyon (France),...